A New Drug May Stimulate the Immune System to Attack Pancreatic Cancer
Researchers are conducting a phase 0 study of a new drug that may cause inflammation to stimulate immune system against cancer.
Researchers are conducting a phase 0 study of a new drug that may cause inflammation to stimulate immune system against cancer.
Researchers are testing a new antibody, a type of targeted therapy, in combination with standard treatment for pancreatic cancer in a phase III trial.
Scientists are trying a new type of drug combination that gets activated only in the unique conditions of the tumor microenvironment.
A clinical trial tests a precision radiation technique called intensity-modulated radiation therapy against locally advanced pancreatic cancer.
In this observational study, researchers are looking at whether irreversible electroporation (also known as IRE) added to standard treatment is more effective at treating pancreatic cancer. How IRE Works Irreversible electroporation (brand name NanoKnife) is a method of removing body tissue using high-energy pulses of electricity. The electrical pulses create permanent pores in the membranes…
Researchers are comparing standard radiotherapy treatment with a newer type of radiation that uses heavy ions, for nonsurgical pancreatic cancer patients.
A clinical trial is testing a new drug combination that damages the tumor blood vessels and allows chemotherapy drugs to enter the tumor.
Wasting, or cachexia, is the focus of a clinical trial testing a cachexia immunotherapy treatment combined with standard pancreatic cancer treatment.
Researchers are combining immunotherapy and targeted therapy in a clinical trial for pancreatic cancer patients on platinum-based chemotherapy.
A clinical trial uses electric fields to help slow the growth of tumor cells, In a clinical trial for pancreatic cancer patients.